NCT06488521View on ClinicalTrials.gov

A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

September 30, 2025

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

Complarate

Complarate solution, a subcutaneous injection at a single dose of 162 mg.

BIOLOGICAL

Actemra®

Actemra® solution, subcutaneous injection at a single dose of 162 mg.

Trial Locations (3)

117556

"State budgetary healthcare institution of the city of Moscow City Clinic No. 2 of the Moscow Health Department", Moscow

119435

Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov Ministry of Health of Russia, Moscow

194156

"LLC X Seven Clinical Research", Saint Petersburg

All Listed Sponsors
lead

AO GENERIUM

INDUSTRY

NCT06488521 - A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers | Biotech Hunter | Biotech Hunter